HIV Vaccination, is Breakthrough Underway?

Lu, Da-Yong; Wu, Hongying; Lu, Ting-Ren; Xu, Biao; Ding, Jian

doi:10.2174/1574887111666151217125154

Cited by 7 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most mortality impacts of HIV-induced pathogenesis might be virus-human genome penetrations in infected cells or tissues, which are irreversible by present clinical therapeutics [4][5][6]. But they are the targets of many biotherapies [17][18][19][20]. Despite great promises, this hypothesis has been just systematically studied.…”

Section: Next Generation Sequencingmentioning

confidence: 99%

HIV in Human Genomes and Therapeutics

Lu¹,

Lü²,

Yarla³

et al. 2017

HIV Curr Res

Self Cite

View full text Add to dashboard Cite

One of the most interesting topics in the field of HIV/AIDS study is the possible relationship between HIV genetic penetrations and disease stages. One decade before, this kind of genomic information is difficult to achieve. Yet, the innovations of next generation sequencing (NGS) have changed this landscape. At present, new generations of bio-therapies target this undesired pathogenic pathways. In this article, we address the relationships between HIV-induced genomic changes across the history and different types of therapeutics have been testified since last decade-including integrate inhibitors, genome editing agents and therapeutic schedules. Future perspectives are also given. HIV in Human Genomes and Therapeutics Knowledge EvolutionPhysical states of DNA polymers in pathologic and therapeutic studiesAt the beginning of this millennium, genomic drafting was a huge task hardly finished by single lab or even an institute. Owing to this situation, physical states of DNA samples were used to identify smallsegments of HIV genome integration into physical states of DNA polymers. In these initial studies, a great amount of HIV pieces can penetrate into DNA polymers as fast as 4 hrs [4]. By utility of this experimental model, a series of HIV/AIDS therapeutic agents (integrate inhibitors) have been developed and finally licensed [4-6,14-17].Since integrase inhibitors were usually developed by DNA polymer substrate techniques, the situation of clinical therapeutic improvements were uncertainty. It means that DNA polymer conditions are not completely parallel with complicate conditions in living cells and bodies-including HIV infected patients. As a result, more sophisticate living conditions (in vitro or in vivo experimental models) must be established, and even utilized as HIV therapeutic drug evaluating systems. Different types of animal models and human cell modelsBefore clinical human genomic pathological and therapeutic studies, in vitro or in vivo animal models for HIV genomic integration must be utilized first. In animal model studies, selections of animal genomic origin and human cell/tissue types are important.There are similarity and diversity among different animal genomic origins and human cell types. These types of animal/human genomic studies generally needs less ethical requirements and can be studied in repeat ways comparing with clinical human investigations. In our opinions, these types of HIV genomic penetration studies should be emphasized now and in future. Similarly, these types of HIV animal

show abstract

Section: Next Generation Sequencingmentioning

confidence: 99%

HIV in Human Genomes and Therapeutics

Lu¹,

Lü²,

Yarla³

et al. 2017

HIV Curr Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…One possible final solution of curing HIV/AIDS might depend on employing effective HIV vaccines [12][13][14][15][16][17][18].…”

Section: Biotherapeutics Under Investigations Antibody Strategiesmentioning

confidence: 99%

HIV Biotherapy and Natural Chemotherapeutic Agents

Lu¹,

Yu²,

Lü³

et al. 2017

HIV Curr Res

Self Cite

View full text Add to dashboard Cite

Due to the limitation of present HIV/AIDS chemotherapies (incurable for HIV infected patients), new types of anti-HIV agents or clinical therapeutic strategies are desperately needed. Developing anti-HIV drugs of highly activity and penetrable into HIV-infected human cells and tissues is indispensable. HIV biotherapy and natural chemotherapeutic agents are those types of therapeutics. This article addresses the topics of HIV biotherapy and natural chemotherapeutic drug developments-including antibody or interferon therapy, modern diagnosis, genomic editing, Traditional Chinese Medicine, drug developmental pipeline innovation and so on.

show abstract

“…Though no new route has been suggested, it is a fittest model in the course of HIV origin and epidemics as we can imagine. Much similar creative ideas need to be given and proved [13][14][15].…”

Section: Cooperative Transforming Modelsmentioning

confidence: 99%